Ovarian malignant tumors (before and after neoadjuvant chemotherapy for advanced stage, platinum-sensitive recurrence, platinum-resistant recurrence) 2. Cervical cancer (primary treatment for advanced stage, recurrent metastasis) 3. Endometrial cancer (primary treatment for advanced stage, recurrent metastasis) 4. Uterine sarcoma (initial treatment, recurrent metastasis)
Conditions
Interventions
Refractory and Recurrent Endometrial Cancer Group:None
Refractory and Recurrent Ovarian Malignant Tumor Group:None
Refractory and Recurrent Uterine Sarcoma Group:None
Refractory and Recurrent Cervical Cancer Group:None
Sponsors
HenanCancerHospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.The subjects voluntarily joined this clinical study and signed an informed consent form, were able to cooperate with follow-up, and had good compliance; 2.Women aged 18-75 (including 18 and 75 years old, calculated on the day of signing informed consent); 3.Ovarian malignant tumors (before and after neoadjuvant chemotherapy for advanced stage, platinum-sensitive recurrence, platinum-resistant recurrence) 2. Cervical cancer (primary treatment for advanced stage, recurrent metastasis) 3. Endometrial cancer (primary treatment for advanced stage, recurrent metastasis) 4. Uterine sarcoma (initial treatment, recurrent metastasis); 4.ECOG rating: 0-1 points; 5.Expected survival period >= 3 months;
Exclusion criteria
Exclusion criteria: 1.Previous (within 5 years) or concurrent untreated malignant tumors, excluding cured skin basal cell carcinoma and carcinoma in situ; 2.Known cases of brain metastasis or meningeal metastasis (excluding those with stable disease control for >= 4 weeks after radiotherapy or surgery for brain metastasis);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Response (CR);Partial Response (PR);Progressive Disease (PD);Stable Disease (SD),;Not Evaluable (NE); | — |
Secondary
| Measure | Time frame |
|---|---|
| Individual organoid in vitro drug sensitivity results (images), tumor inhibition rate.; | — |
Countries
China
Contacts
Public ContactWEIBING
HenanCancerHospital
Outcome results
None listed